ptis Therapeutics (COEP) - 2025 Q2 - Quarterly Report

PART I – FINANCIAL INFORMATION Item 1. Unaudited Financial Statements This section presents the unaudited condensed consolidated financial statements of Coeptis Therapeutics Holdings, Inc. for the quarter ended June 30, 2025, including balance sheets, statements of operations, stockholders' equity, and cash flows, along with detailed notes explaining the company's business, accounting policies, and financial instruments Condensed Consolidated Balance Sheets This section presents the company's financial position, detailing assets, liabilities, and stockholders' equity at specific dates Condensed Consolidated Balance Sheets (as of June 30, 2025 vs. December 31, 2024) | Metric | June 30, 2025 | December 31, 2024 | | :-------------------------- | :------------ | :-------------- | | ASSETS | | | | Total Current Assets | $3,694,935 | $1,051,292 | | Total Other Assets | $8,486,377 | $7,846,908 | | TOTAL ASSETS | $12,191,479 | $8,908,660 | | LIABILITIES | | | | Total Current Liabilities | $4,475,225 | $4,513,309 | | Total Long Term Liabilities | $636,124 | $528,125 | | TOTAL LIABILITIES | $5,111,349 | $5,041,434 | | STOCKHOLDERS' EQUITY | | | | Total Stockholders' Equity | $7,080,130 | $3,867,226 | Condensed Consolidated Statements of Operations This section details the company's financial performance, including sales, gross profit, operating expenses, and net loss for the specified periods Condensed Consolidated Statements of Operations (Three Months Ended June 30) | Metric | June 30, 2025 | June 30, 2024 | | :-------------------------------- | :------------ | :------------ | | Sales | $200,681 | $0 | | Gross profit | $155,524 | $0 | | Total cost of operations | $4,676,738 | $2,828,102 | | Loss from operations | $(4,521,214) | $(2,828,102) | | Total other income (expense), net | $186,628 | $(207,243) | | Net loss | $(4,334,586) | $(3,035,345) | | Loss per share, basic and diluted | $(1.17) | $(0.08) | Condensed Consolidated Statements of Operations (Six Months Ended June 30) | Metric | June 30, 2025 | June 30, 2024 | | :-------------------------------- | :------------ | :------------ | | Sales | $263,555 | $0 | | Gross profit | $173,242 | $0 | | Total cost of operations | $8,751,440 | $5,750,485 | | Loss from operations | $(8,578,198) | $(5,750,485) | | Total other income (expense), net | $822,671 | $(286,248) | | Net loss | $(7,755,527) | $(6,036,733) | | Loss per share, basic and diluted | $(2.29) | $(0.17) | Condensed Consolidated Statements of Stockholders' Equity This section outlines changes in the company's equity, including capital raises, debt conversions, stock-based compensation, and net loss, over the reporting period Key Changes in Stockholders' Equity (Six Months Ended June 30, 2025) | Item | Change | | :-------------------------------- | :------------ | | Balance at December 31, 2024 | $3,867,226 | | Series A Preferred Stock Offering | $5,330,000 | | Pre-funded warrants exercise | $500 | | Debt converted to equity | $1,253,112 | | Shares Issued for Services | $2,382,569 | | Stock based compensation | $788,753 | | Net loss | $(7,755,527) | | Balance at June 30, 2025 | $7,080,130 | Condensed Consolidated Statements of Cash Flows This section presents the company's cash inflows and outflows from operating, investing, and financing activities, showing the net change in cash over the period Condensed Consolidated Statements of Cash Flows (Six Months Ended June 30) | Activity | June 30, 2025 | June 30, 2024 | | :-------------------------------- | :------------ | :------------ | | Net cash used in operating activities | $(4,762,909) | $(3,320,121) | | Net cash used in investing activities | $0 | $(100,000) | | Net cash provided by financing activities | $6,226,750 | $3,506,062 | | Net increase (decrease) in cash | $1,463,841 | $85,941 | | Cash at end of period | $1,996,726 | $1,555,075 | Condensed Consolidated Notes to Unaudited Financial Statements This section provides detailed explanations and disclosures regarding the company's accounting policies, financial instruments, and other significant financial information NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Coeptis Therapeutics Holdings, Inc. operates as a biopharmaceutical and technology company through its subsidiaries. The biopharmaceutical division develops cell therapy platforms for various diseases, while the technology division focuses on AI-powered marketing software and robotic process automation. The company completed a 20-1 reverse stock split on December 31, 2024, retrospectively applied to all financial statements - Coeptis is a biopharmaceutical and technology company. The biopharmaceutical division develops innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. The technology division features AI-powered marketing software and robotic process automation tools[20] - The company operates through wholly-owned subsidiaries Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., and Coeptis Pharmaceuticals, LLC, and majority-owned subsidiaries SNAP Biosciences, Inc. and GEAR Therapeutics, Inc[19][22] - A 20-1 reverse stock split of issued and outstanding common stock was completed on December 31, 2024, and retrospectively applied to all share and per-share amounts[23] NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES This note outlines the company's significant accounting policies, including the use of estimates, employee and non-employee share-based compensation, revenue recognition, accounts receivable, investments, and marketable securities. It also highlights a going concern issue due to accumulated deficit and net losses, indicating reliance on future capital raises - Revenue is recognized when control of promised goods and services is transferred to customers, primarily from data research, advertising campaigns via cold emails and social media, and webinar services[29][30] Revenue Recognition (Six Months Ended June 30, 2025) | Service Type | Revenue | | :-------------------------------- | :------------ | | Advertising campaigns | $218,555 | | Webinar services | $45,000 | | Total Sales | $263,555 | - The company had an accumulated deficit of $105,989,201 and a net loss of $7,755,527 for the six months ended June 30, 2025, raising substantial doubt about its ability to continue as a going concern. Management plans to raise additional capital through equity or debt[37] NOTE 3 – CO-DEVELOPMENT RIGHTS The company terminated a license agreement with Purple Biotech and secured exclusive worldwide development and commercialization rights to the GEAR™ Cell Therapy Platform from Vy-Gen-Bio, Inc. This platform is a first-in-class approach for modifying cancer-targeting immune cells - The license termination agreement with Purple Biotech for the Consensi product was executed in September 2021, and the outstanding convertible note balance of $218,750 was paid in full during Q1 2025[38] - In March 2025, Coeptis licensed exclusive worldwide development and commercialization rights to the GEAR™ (Gene Edited Antibody Resistant) Cell Therapy Platform from Vy-Gen-Bio, Inc., committing to a $100,000 license fee by August 1, 2025, plus future milestone and royalty payments[42] Co-Development Rights (as of June 30, 2025) | Metric | Amount | | :-------------------------------- | :------------ | | Total gross capitalized Co-Development rights | $5,291,667 | | Accumulated amortization | $(4,237,500) | | Net carrying amount | $1,054,167 | NOTE 4 – NOTES PAYABLE The company has an outstanding convertible promissory note of $100,000 for legal services, which was in default as of June 30, 2025 - An outstanding convertible promissory note of $100,000 for legal services was in default as of June 30, 2025[45] NOTE 5 – CONVERTIBLE NOTES The Purple Biotech convertible note was fully satisfied in Q1 2025. The company entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville, which included a convertible promissory note (YA Note-1) that was fully converted into common stock during the six months ended June 30, 2025. A new convertible note (YA Note-2) was issued to Yorkville in January 2025 - The $218,750 outstanding principal balance of the Purple Biotech convertible note was paid in full during the quarter ended March 31, 2025[46] - Yorkville converted the entire outstanding principal balance of $1,304,758 on YA Note-1, along with $52,505 of accrued interest, into 233,500 shares of common stock during the six months ended June 30, 2025[49] - A new convertible promissory note (YA Note-2) for $1,100,000 was entered into with Yorkville on January 16, 2025, bearing 8% annual interest and maturing on December 31, 2025[55] Derivative Liability Fair Value | Date | Fair Value | | :-------------------------------- | :------------ | | December 31, 2024 | $1,041,484 | | June 30, 2025 | $0 | | Change in fair value (6 months ended June 30, 2025) | $(906,429) | | Extinguishment of fair value of liability | $(135,055) | NOTE 6 – SBA LOAN PAYABLE The company has an outstanding SBA Economic Injury Disaster Loan (EIDL) of $150,000, received in July 2020, with interest accruing at 3.75% per annum - The balance of the SBA EIDL loan is $150,000 as of June 30, 2025, and December 31, 2024, with interest at 3.75% per annum[60] NOTE 7 – DERIVATIVE LIABILITY WARRANTS The company accounts for its Public Warrants and Private Placement Warrants as derivative liabilities, measured at fair value using a binomial lattice model. The fair value of these warrants increased from $359,250 at December 31, 2024, to $467,250 at June 30, 2025 - The company has 375,000 Public Warrants and 187,500 Private Placement Warrants outstanding, adjusted for a 20-1 reverse stock split[61] - Public Warrants and Private Placement Warrants are accounted for as derivative liabilities and measured at fair value using a binomial lattice model[66][67] Derivative Liability Warrants Fair Value | Description | June 30, 2025 | December 31, 2024 | | :-------------------------------- | :------------ | :-------------- | | Warrant Liability – Public Warrants | $216,000 | $165,000 | | Warrant Liability – Private Placement Warrants | $251,250 | $194,250 | | Total | $467,250 | $359,250 | NOTE 8 – CAPITAL STRUCTURE The company's capital structure includes 150,000,000 authorized common shares and 10,000,000 authorized preferred shares. As of June 30, 2025, 4,166,713 common shares and 625 Series A preferred shares were outstanding. The company completed a $10.0 million Series A preferred stock offering and entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville for up to $20.0 million in common stock sales Common and Preferred Stock Outstanding | Stock Type | June 30, 2025 | December 31, 2024 | | :-------------------------------- | :------------ | :-------------- | | Common Stock | 4,166,713 shares | 2,116,191 shares | | Preferred Stock (Series A) | 625 shares | 6,250 shares | - The company completed its $10.0 million Series A preferred stock offering on February 6, 2025. Throughout the six months ended June 30, 2025, 9,375 shares of the 10,000 Series A preferred shares were converted to common stock[79] - The company entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville on November 1, 2024, allowing the sale of up to $20,000,000 of common stock, subject to limitations[97] NOTE 9 – NON-CONTROLLING INTEREST Non-controlling interest of $984,300 was recorded at June 30, 2025, due to the Series A preferred stock offering, which granted Series A Investors a 15% non-voting equity ownership in SNAP Biosciences, Inc. and GEAR Therapeutics, Inc - Non-controlling interest of $984,300 was recorded at June 30, 2025, reflecting the 15% non-voting equity ownership of Series A Investors in SNAP Biosciences, Inc. and GEAR Therapeutics, Inc[104] NOTE 10 – INVESTMENTS The company holds investments in privately held companies, totaling $6,941,083 at June 30, 2025, primarily from settling subscription receivables and master services agreements. It also recorded marketable securities of $600,000 from a customer contract, with an unrealized gain of $390,566 Investments (as of June 30, 2025 vs. December 31, 2024) | Investment Type | June 30, 2025 | December 31, 2024 | | :-------------------------------- | :------------ | :-------------- | | Investments in privately held companies | $6,941,083 | $5,691,084 | | Marketable securities | $990,566 | $0 | | Unrealized gain on marketable securities (6 months ended June 30, 2025) | $390,566 | N/A | - Investments in privately held companies were acquired through the satisfaction of subscription receivables and master services agreements for access to the NexGenAI Affiliates Network platform[105] NOTE 11 – COMMITMENTS AND CONTINGENCIES The company has an operating lease for office space extending to May 2026. It holds exclusive license agreements with the University of Pittsburgh for SNAP-CAR T-cell and NK cell technology, and with Deverra Therapeutics for an allogeneic stem cell expansion platform. SNAP Biosciences also entered a grant agreement with Karolinska Institutet and a license agreement with Monarch Therapeutics. The company has master services agreements for its NexGenAI platform - The office lease was extended to May 31, 2026, with monthly rent increasing from $3,805 to $3,860[107] - Exclusive license agreements with the University of Pittsburgh for SNAP-CAR T-cell and NK cell technology involve annual maintenance fees and potential milestone/royalty payments[110][113] - SNAP Biosciences entered a grant agreement with Karolinska Institutet for pre-clinical and clinical development, with quarterly payments of $105,000, and a license agreement with Monarch Therapeutics for small-molecule adaptor-based technology[111][112] - The company entered into one-year Master Services Agreements with five customers on December 31, 2024, to provide access to the NexGenAI Affiliates Network platform, with a total contract value of approximately $1.6 million[119] NOTE 12 – 401(k) PROFIT-SHARING PLAN The company sponsors a 401(k) profit-sharing plan for eligible employees, but no employer contributions were made during the six months ended June 30, 2025, or 2024 - The company sponsors a 401(k) profit-sharing plan; no employer contributions were made during the six months ended June 30, 2025, and 2024[120] NOTE 13 – INCOME TAXES No income tax expense or benefit was recognized for the six months ended June 30, 2025, and 2024, as the company maintains a full valuation allowance on its deferred tax assets due to a lack of sustained profitable operations - No income tax expense or benefit was recognized for the six months ended June 30, 2025, and 2024, due to a full valuation allowance on deferred tax assets[121] NOTE 14 – RELATED PARTY TRANSACTION The company engaged in a transaction with AG Bio Life Capital I LP, where an employee is the general partner, which was settled by transferring shares in a privately held company. Additionally, the CEO and CFO hold ownership interests in certain privately held companies where the company also has investments - A transaction with AG Bio Life Capital I LP, a related party, was settled by transferring $522,667 in shares of a privately held company[122] - The company's CEO and CFO hold ownership interests in certain privately held companies in which the company also has investments[123] NOTE 15 – INTANGIBLE ASSETS On December 19, 2024, the company acquired the assets of NexGenAI Affiliates Network Platform, including AI-powered marketing software and robotic process automation capabilities, for 187,500 shares of common stock valued at $541,875, recorded as intangible assets - The company acquired NexGenAI Affiliates Network Platform assets, including AI-powered marketing software, for 187,500 shares of common stock ($541,875), recorded as intangible assets[124][125] NOTE 16 – SEGMENT REPORTING Effective 2024, the company operates in two segments: Biotechnology (non-revenue generating, focused on product pipeline development) and Technology (revenue generating, focused on advanced technologies like AI-powered marketing software) - Effective 2024, the company operates in two segments: Biotechnology (non-revenue generating) and Technology (revenue generating)[126] Segment Assets (as of June 30, 2025 vs. December 31, 2024) | Segment | June 30, 2025 | December 31, 2024 | | :-------------------------------- | :------------ | :-------------- | | Biotechnology Segment | $9,083,207 | $8,366,785 | | Technology Segment | $2,692,129 | $541,875 | Segment Sales and Net Loss from Operations (Six Months Ended June 30, 2025) | Segment | Sales | Net Loss from Operations | | :-------------------------------- | :------------ | :----------------------- | | Technology Segment | $263,555 | $(8,428,087) | | Biotechnology Segment | $0 | $(150,111) | | Consolidated | $263,555 | $(8,578,198) | NOTE 17 – PENDING MERGER TRANSACTION On April 25, 2025, the company entered into a merger agreement with Z Squared, Inc., which involves a spin-out of Coeptis' biotechnology operations to its stockholders and Z Squared becoming a wholly-owned subsidiary. The merger is expected to close in 2025 - The company entered into a Merger Agreement with Z Squared, Inc. on April 25, 2025[131] - The transaction includes a spin-out of Coeptis' biotechnology operations to its stockholders and Z Squared becoming a wholly-owned subsidiary[132][134] NOTE 18 – SUBSEQUENT EVENTS Subsequent events after June 30, 2025, include the commencement of a private placement common stock offering ($2.5M-$5M), Yorkville's conversion of the January 2025 convertible note into 158,582 common shares, an amendment to a consulting agreement by offsetting a $125,000 subscription receivable, and the conversion of the final 625 Series A preferred shares to common stock - On July 11, 2025, the company commenced a private placement common stock offering with a minimum of $2,500,000 and a maximum of $5,000,000[137] - On July 14, 2025, Yorkville converted $1,143,397 of the January 2025 convertible promissory note into 158,582 shares of common stock[139] - On July 29, 2025, the final 625 shares of Series A preferred stock were converted to common stock[141] Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations This section provides management's perspective on the company's financial condition, results of operations, cash flows, and liquidity for the periods presented. It highlights the company's strategic shift towards biopharmaceutical and technology segments, the impact of the NexGenAI platform on revenue, and the ongoing efforts to raise capital Overview and Outlook Coeptis is a biopharmaceutical and technology company focused on cell therapy technologies. It has shifted away from generic products and is investing in innovative products. The company faced operational challenges due to the COVID-19 pandemic, which impacted product launches and sales - The company is a biopharmaceutical and technology company that owns, acquires, and develops cell therapy technologies for cancer and other diseases[150] - Coeptis has moved away from commercializing generic products, having divested ANDA products in 2019 and abandoned activities related to previously commercialized 505b2 products due to COVID-19 impacts[150][151] Biotechnology Segment The Biotechnology Segment focuses on developing CD38-GEAR-NK (an autologous NK cell therapeutic for CD38-related cancers) and CD38-Diagnostic (an in vitro screening tool) with Vy-Gen-Bio, Inc. The company recently secured exclusive worldwide rights to the GEAR™ Cell Therapy Platform. It also has licensing arrangements with Deverra Therapeutics for an allogeneic stem cell expansion platform - CD38-GEAR-NK is an autologous, gene-edited, NK cell-based therapeutic designed to protect CD38+ NK cells from destruction by anti-CD38 monoclonal antibodies, targeting CD38-related cancers like multiple myeloma[153][160] - CD38-Diagnostic is an in vitro diagnostic tool to identify cancer patients suitable for anti-CD38 mAb therapy, designated as a Class II device by the FDA[156][159] - In March 2025, the company licensed exclusive worldwide development and commercialization rights to the GEAR™ Cell Therapy Platform from Vy-Gen-Bio, Inc[163] - The company entered an exclusive licensing arrangement with Deverra Therapeutics Inc. for a proprietary allogeneic stem cell expansion and directed differentiation platform, including two IND applications and Phase 1 clinical trial programs[164] Technology Segment The Technology Segment was established through the acquisition of the NexGenAI Affiliates Network Platform in December 2024. This platform provides AI-powered marketing software and robotic process automation capabilities, enabling the company to offer managed digital marketing services - The company acquired the NexGenAI Affiliates Network Platform in December 2024, which includes AI-powered marketing software and robotic process automation capabilities[168] - The platform supports managed digital marketing services such as lead generation, content marketing, social media marketing, and marketing analytics[169] Our Results of Operations The company has generated minimal revenue primarily from consulting and product sales, with uncertainty regarding future sales covering expenses. Operating expenses, particularly general and administrative, are expected to increase due to business growth and public company operations, while research and development costs will depend on strategic collaborations - Revenue has been minimal, mostly from consulting arrangements and product sales, with uncertainty about current marketed products generating sufficient sales to cover expenses[171] - General and administrative expenses are expected to increase due to business growth, increased headcount, and costs associated with operating as a public company[172] - Research and development costs are expected to increase to support new strategic initiatives and collaborations[173] Comparison of the three months ended June 30, 2025 and June 30, 2024 For the three months ended June 30, 2025, revenues remained minimal but started generating from the NexGenAI platform. Operating expenses increased significantly, driven by professional services related to the Merger Agreement, while stock-based compensation and R&D expenses decreased. The company recognized a gain from the change in fair value of derivative liabilities - Revenues remained minimal but started generating from the NexGenAI platform in Q1 2025[174] Operating Expenses (Three Months Ended June 30) | Expense Type | June 30, 2025 | June 30, 2024 | Change (YoY) | | :-------------------------------- | :------------ | :------------ | :----------- | | Total Operating Expenses | $4,676,738 | $2,828,102 | +65.3% | | Professional services expense | $2,975,620 | $864,588 | +244.2% | | Stock based compensation expense | $191,021 | $611,570 | -68.8% | | Research and development expense | $290,309 | $398,817 | -27.3% | Change in Fair Value of Derivative Liabilities (Three Months Ended June 30) | Period | Amount | | :-------------------------------- | :------------ | | June 30, 2025 | $202,310 (gain) | | June 30, 2024 | $(149,250) (loss) | Comparison of the six months ended June 30, 2025 and June 30, 2024 For the six months ended June 30, 2025, revenues increased significantly due to the Technology segment. Operating expenses rose, primarily from professional services, while interest expense decreased. The company recorded a substantial gain from the change in fair value of derivative liabilities Revenues (Six Months Ended June 30) | Period | Amount | | :-------------------------------- | :------------ | | June 30, 2025 | $263,555 | | June 30, 2024 | $0 | | Change (YoY) | +$263,555 | Operating Expenses (Six Months Ended June 30) | Expense Type | June 30, 2025 | June 30, 2024 | Change (YoY) | | :-------------------------------- | :------------ | :------------ | :----------- | | Total Operating Expenses | $8,751,440 | $5,750,485 | +52.2% | | Professional services expense | $5,301,187 | $2,045,087 | +159.2% | | Stock based compensation expense | $788,752 | $708,459 | +11.3% | | Research and development expense | $376,968 | $1,175,886 | -67.9% | Interest Expense (Six Months Ended June 30) | Period | Amount | | :-------------------------------- | :------------ | | June 30, 2025 | $(139,279) | | June 30, 2024 | $(266,561) | | Change (YoY) | -47.8% | Change in Fair Value of Derivative Liabilities (Six Months Ended June 30) | Period | Amount | | :-------------------------------- | :------------ | | June 30, 2025 | $798,430 (gain) | | June 30, 2024 | $(114,375) (loss) | Financial Resources and Liquidity The company's cash and cash equivalents increased to $1,996,726 at June 30, 2025, from $1,555,075 at June 30, 2024. Management plans to increase liquidity through equity transactions to fund operations and execute its operating strategy Cash and Cash Equivalents | Period | Amount | | :-------------------------------- | :------------ | | June 30, 2025 | $1,996,726 | | June 30, 2024 | $1,555,075 | | Change (YoY) | +$441,651 | - The company believes that raising capital through equity transactions in 2025 will increase liquidity and enable the execution of management's operating strategy[183] Item 3. Quantitative and Qualitative Disclosures About Market Risk As a smaller reporting company, Coeptis Therapeutics Holdings, Inc. is not required to provide quantitative and qualitative disclosures about market risk - The company is a smaller reporting company and is not required to provide quantitative and qualitative disclosures about market risk[184] Item 4. Controls and Procedures Management, including the CEO and CFO, evaluated the effectiveness of the company's disclosure controls and procedures as of June 30, 2025. Following remediation efforts for previously identified material weaknesses in internal control over financial reporting, they concluded that the disclosure controls and procedures were effective - The company's management, including the CEO and CFO, concluded that disclosure controls and procedures were effective as of June 30, 2025[188] - Remediation efforts for self-identified material weaknesses in internal control over financial reporting as of December 31, 2023, included hiring additional resources, documenting accounting policies, and adopting processes for timely financial statement close and secondary reviews[186][187] PART II – OTHER INFORMATION Item 1. Legal Proceedings The company is not currently a defendant in any litigation or threatened litigation that could materially affect its condensed consolidated financial statements - The company is not a defendant in any material legal proceedings[192] Item 1A. Risk Factors For a comprehensive discussion of risk factors that could materially affect the company's business, financial condition, or future results, readers are directed to Part I, 'Item 1A. Risk Factors' in the Annual Report on Form 10-K for the year ended December 31, 2024 - Readers should refer to the Annual Report on Form 10-K for the year ended December 31, 2024, for a comprehensive discussion of risk factors[193] Item 2. Unregistered Sales of Equity Securities and Use of Proceeds All prior sales of unregistered securities have been properly disclosed in previous SEC filings - All prior sales of unregistered securities have been properly disclosed in prior SEC filings[194] Item 3. Defaults Upon Senior Securities This item is not applicable to the company - This item is not applicable[195] Item 4. Mine Safety Disclosures This item is not applicable to the company - This item is not applicable[196] Item 5. Other Information During the quarter ended June 30, 2025, no director or officer of the company adopted or terminated a 'Rule 10b5-1 trading arrangement' or 'non-Rule 10b5-1 trading arrangement' - No director or officer adopted or terminated a 'Rule 10b5-1 trading arrangement' or 'non-Rule 10b5-1 trading arrangement' during the quarter ended June 30, 2025[197] Item 6. Exhibits This section lists the exhibits filed as part of this Form 10-Q, including certifications from the Chief Executive Officer and Chief Financial Officer, and various XBRL taxonomy extension documents - Exhibits include Rule 13a-14(a)/15(d)-14(a) Certifications, Section 1350 Certifications from the CEO and CFO, and XBRL Instance, Schema, Calculation, Definition, Label, and Presentation Linkbase documents[198] SIGNATURES SIGNATURES The report is duly signed on behalf of Coeptis Therapeutics Holdings, Inc. by David Mehalick, Chief Executive Officer, and Brian Cogley, Chief Financial Officer, on August 14, 2025 - The report is signed by David Mehalick, Chief Executive Officer, and Brian Cogley, Chief Financial Officer, on August 14, 2025[200]